Clinical evaluation of the first oxycodone once daily prolonged release tablet in moderate to severe chronic pain: a randomized, double-blind, multicenter, cross-over, non-inferiority study to investigate efficacy and safety in comparison with an established oxycodone twice daily prolonged release tablet

References

• WHO. Treatment Guidelines on Chronic Non-Malignant Pain in Adults. 2008. Available at: http://www.who.int/medicines/areas/quality_safety/Scoping_WHOGuide_non-malignant_pain_adults.pdf [Last accessed 1 February 2014]
   Google Scholar
• WHO. Normative Guidelines on Pain Management. Report of a Delphi Study to Determine the Need for Guidelines and to Identify the Number and Topics of Guidelines That Should Be Developed by WHO. 2007. Available at: http://www.who.int/medicines/areas/quality_safety/delphi_study_pain_guidelines.pdf [Last accessed 1 February 2014]
   Google Scholar
• Johnson M, Collett B, Castro-Lopes JM. The challenges of pain management in primary care: a pan-European survey. J Pain Res 2013;6:393-401
   PubMed Web of Science ®Google Scholar
• Thapa D, Rastogi V, Ahuja V. Cancer pain management – current status. J Anaesthesiol Clin Pharmacol 2011;27:162-8
   PubMedGoogle Scholar
• Pergolizzi J, Boger RH, Budd K, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract 2008;8:287-313
   PubMedGoogle Scholar
• Levy MH. Advancement of opioid analgesia with controlled-release oxycodone. Eur J Pain 2001;5(Suppl A):113-16
   PubMedGoogle Scholar
• Coluzzi F, Mattia C. Chronic non-cancer pain: focus on once-daily tramadol formulations. Ther Clin Risk Manag 2007;3:819-29
   PubMedGoogle Scholar
• Coluzzi F, Mattia C. OROS(R) hydromorphone in chronic pain management: when drug delivery technology matches clinical needs. Minerva Anestesiol 2010;76:1072-84
   PubMed Web of Science ®Google Scholar
• Cramer MP, Saks SR. Translating safety, efficacy and compliance into economic value for controlled release dosage forms. Pharmacoeconomics 1994;5:482-504
   PubMed Web of Science ®Google Scholar
• Stambaugh JE, Reder RF, Stambaugh MD, et al. Double-blind, randomized comparison of the analgesic and pharmacokinetic profiles of controlled- and immediate-release oral oxycodone in cancer pain patients. J Clin Pharmacol 2001;41:500-6
   PubMed Web of Science ®Google Scholar
• Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-310
   PubMed Web of Science ®Google Scholar
• Panjabi SS, Panjabi RS, Shepherd MD, et al. Extended-release, once-daily morphine (Avinza) for the treatment of chronic nonmalignant pain: effect on pain, depressive symptoms, and cognition. Pain Med 2008;9:985-93
   PubMed Web of Science ®Google Scholar
• Data on file. Comparative bioavailability studies of oxycodone after single/multiple oral administration of Oxycodone HCl 10 mg PR tablets XL (Develco Pharma Schweiz AG) and single/multiple oral administration two times daily of Oxygesic® 5 mg tablets (Mundipharma GmbH, Germany) under fasting/fed conditions in healthy subjects. Clinical Study Reports by Scheidel B et al., 683B8, 684B8, and 685B8 of 28-Apr-2010
   Google Scholar
• Data on file. Dose proportionality studies of oxycodone after single oral administration of Oxycodone HCl 10 mg PR tablets XL, Oxycodone HCl 20 mg PR tablets XL,Oxycodone HCl 40 mg PR tablets XL, and Oxycodone HCl 80 mg PR tablets XL (Develco Pharma Schweiz AG) under fasting conditions in healthy subjects. Clinical Study Reports by Scheidel B et al., 686B8 of 22-Oct-2010 and 265B12 of 22-Nov-2012
   Google Scholar
• Bingham CO 3rd, Sebba AI, Rubin BR, et al. Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. Rheumatology (Oxford) 2007;46:496-507
   PubMed Web of Science ®Google Scholar
• Fardellone P, Zaim M, Saurel AS, Maheu E. Comparative efficacy and safety study of two chondroitin sulfate preparations from different origin (avian and bovine) in symptomatic osteoarthritis of the knee. Open Rheumatol J 2013;7:1-12
   PubMedGoogle Scholar
• Hale ME, Ahdieh H, Ma T, Rauck R. Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study. J Pain 2007;8:175-84
   PubMed Web of Science ®Google Scholar
• Hagen NA, Babul N. Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer 1997;79:1428-37
   PubMed Web of Science ®Google Scholar
• Grosset AB, Roberts MS, Woodson ME, et al. Comparative efficacy of oral extended-release hydromorphone and immediate-release hydromorphone in patients with persistent moderate to severe pain: two randomized controlled trials. J Pain Symptom Manage 2005;29:584-94
   PubMed Web of Science ®Google Scholar
• Bruera E, Belzile M, Pituskin E, et al. Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain. J Clin Oncol 1998;16:3222-9
   PubMed Web of Science ®Google Scholar
• Finn JW, Walsh TD, MacDonald N, et al. Placebo-blinded study of morphine sulfate sustained-release tablets and immediate-release morphine sulfate solution in outpatients with chronic pain due to advanced cancer. J Clin Oncol 1993;11:967-72
   PubMed Web of Science ®Google Scholar
• Bouhassira D, Attal N, Alchaar H, et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain 2005;114:29-36
   PubMed Web of Science ®Google Scholar
• Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55
   PubMed Web of Science ®Google Scholar
• Bauer P, Kohne K. Evaluation of experiments with adaptive interim analyses. Biometrics 1994;50:1029-41
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Turk DC, Peirce-Sandner S, et al. Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations. Pain 2012;153:1148-58
   PubMed Web of Science ®Google Scholar
• Jensen MP. The Validity and Reliability of Pain Measures for use in Clinical Trials in Adults: Review Paper Written for the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) meeting, 12–13 April 2003. Available at: http://www.immpact.org/static/meetings/Immpact2/background/Jensen_review.pdf [Last accessed 1 February 2014]
   Google Scholar
• Hsu SK, Yeh CC, Lin CJ, Hsieh YJ. An open label trial of the effects and safety profile of extended-release tramadol in the management of chronic pain. Acta Anaesthesiol Taiwan 2012;50:101-5
   PubMedGoogle Scholar
• Hagg O, Fritzell P, Nordwall A. The clinical importance of changes in outcome scores after treatment for chronic low back pain. Eur Spine J 2003;12:12-20
   PubMed Web of Science ®Google Scholar
• Grilo RM, Treves R, Preux PM, et al. Clinically relevant VAS pain score change in patients with acute rheumatic conditions. Joint Bone Spine 2007;74:358-61
   PubMed Web of Science ®Google Scholar
• Walsh TD, MacDonald N, Bruera E, et al. A controlled study of sustained-release morphine sulfate tablets in chronic pain from advanced cancer. Am J Clin Oncol 1992;15:268-72
   PubMed Web of Science ®Google Scholar
• Ruyssen-Witrand A, Tuback F, Ravaud P. Systematic review reveals heterogeneity in definition of a clinically relevant difference in pain. J Clin Epidemiol 2011;64:463-70
   PubMed Web of Science ®Google Scholar
• Coluzzi PH, Schwartzberg L, Conroy JD, et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain 2001;91:123-30
   PubMed Web of Science ®Google Scholar
• Jensen MP. Meaningful change and meaningful endpoints in pain clinical trials. IMMPACT IV meeting. 2004. Available at: http://www.immpact.org/meetings/Immpact4/background4.html [Last accessed 1 February 2014]
   Google Scholar
• Peloso PM, Gammaitoni A, Smugar SS, et al. Longitudinal numbers-needed-to-treat (NNT) for achieving various levels of analgesic response and improvement with etoricoxib, naproxen, and placebo in ankylosing spondylitis. BMC Musculoskelet Disord 2011;12:165
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008;9:105-21
   PubMed Web of Science ®Google Scholar
• Watson CP, Moulin D, Watt-Watson J, et al. Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain 2003;105:71-8
   PubMed Web of Science ®Google Scholar
• Gimbel JS, Richards P, Portenoy RK. Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology 2003;60:927-34
   PubMed Web of Science ®Google Scholar
• McNicol ED, Midbari A, Eisenberg E. Opioids for neuropathic pain. Cochrane Database Syst Rev 2013;8:CD006146
   PubMed Web of Science ®Google Scholar
• Gatti A, Sabato AF, Occhioni R, et al. Controlled-release oxycodone and pregabalin in the treatment of neuropathic pain: results of a multicenter Italian study. Eur Neurol 2009;61:129-37
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Barbano RL, Tyring SK, et al. A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster. Pain 2009;142:209-17
   PubMed Web of Science ®Google Scholar